GENE ONLINE|News &
Opinion
Blog

Complete Response Letter
Ascendis’ Hormone Drug Hits Another FDA Roadblock on Path to Approval
2023-05-02
FDA Rejects Sesen Bio’s Bladder Cancer Drug Application, Asks Additional Data
2021-08-16
FDA Rejection of Type 1 Diabetes Drug Impacts Provention Bio’s Stocks
2021-07-07
FDA Rejects Protalix’s Enzyme Replacement Therapy for Rare Genetic Disease
2021-04-29
Acadia Fumes Over FDA Rejection of its Psychosis Drug Nuplazid
2021-04-06
FDA Rejects Athenex’s Breast Cancer Treatment, Recommends Another Clinical Trial
2021-03-03
FDA Requests Additional Info for Liquidia’s Pulmonary Arterial Hypertension Treatment
2020-11-27
FDA Rejects BioMarin Pharmaceuticals’ Valoctocogene Roxaparvovec Gene Therapy for Severe Hemophilia A
2020-08-20
With NASH Drug Rejected, Intercept CEO Lambasts FDA’s Evolving Guidelines
2020-07-01
Expedited Approval of Vitrakvi® Marks Many Firsts in Cancer Therapy
2018-12-04
LATEST
Ginkgo Bioworks and Pfizer Forge $331 Million Collaboration for RNA-Based Drug Discovery
2023-09-29
Johnson & Johnson Partners with Singapore to Boost Life Sciences Innovation
2023-09-28
Vietnam and South Korea Strengthen Cooperation in Multiple Sectors
2023-09-27
PeptiDream and Genentech Collaborate on Novel Peptide-Radioisotope Drug Conjugates
2023-09-27
AcuraStem and Takeda Collaborate on Innovative ALS Treatment
2023-09-27
Seven AI/ML for Life Sciences Companies Identified as Innovators in New Clarivate Companies to Watch Report
2023-09-27
GeneOnline’s Weekly News Highlights: Sept 17-Sept 22
2023-09-26
EVENT
2023-10-04
BioFuture 2023
New York city,USA
Scroll to Top